vs
Amphastar Pharmaceuticals, Inc.（AMPH）与CSW INDUSTRIALS, INC.（CSW）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.3倍（$233.0M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 4.4%，领先8.9%），CSW INDUSTRIALS, INC.同比增速更快（20.3% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $22.7M），过去两年CSW INDUSTRIALS, INC.的营收复合增速更高（5.1% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
AMPH vs CSW — 直观对比
营收规模更大
CSW
是对方的1.3倍
$183.1M
营收增速更快
CSW
高出22.1%
-1.8%
净利率更高
AMPH
高出8.9%
4.4%
自由现金流更多
AMPH
多$1.9M
$22.7M
两年增速更快
CSW
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $233.0M |
| 净利润 | $24.4M | $10.3M |
| 毛利率 | 46.8% | 39.7% |
| 营业利润率 | 19.4% | 7.4% |
| 净利率 | 13.3% | 4.4% |
| 营收同比 | -1.8% | 20.3% |
| 净利润同比 | -35.7% | -61.9% |
| 每股收益（稀释后） | $0.51 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHCSW
| Q4 25 | $183.1M | $233.0M | ||
| Q3 25 | $191.8M | $277.0M | ||
| Q2 25 | $174.4M | $263.6M | ||
| Q1 25 | $170.5M | $230.5M | ||
| Q4 24 | $186.5M | $193.6M | ||
| Q3 24 | $191.2M | $227.9M | ||
| Q2 24 | $182.4M | $226.2M | ||
| Q1 24 | $171.8M | $210.9M |
净利润AMPHCSW
| Q4 25 | $24.4M | $10.3M | ||
| Q3 25 | $17.4M | $40.7M | ||
| Q2 25 | $31.0M | $40.9M | ||
| Q1 25 | $25.3M | $35.1M | ||
| Q4 24 | $38.0M | $26.9M | ||
| Q3 24 | $40.4M | $36.1M | ||
| Q2 24 | $37.9M | $38.6M | ||
| Q1 24 | $43.2M | $31.8M |
毛利率AMPHCSW
| Q4 25 | 46.8% | 39.7% | ||
| Q3 25 | 51.4% | 43.0% | ||
| Q2 25 | 49.6% | 43.8% | ||
| Q1 25 | 50.0% | 44.2% | ||
| Q4 24 | 46.5% | 41.4% | ||
| Q3 24 | 53.3% | 45.6% | ||
| Q2 24 | 52.2% | 47.5% | ||
| Q1 24 | 52.4% | 44.4% |
营业利润率AMPHCSW
| Q4 25 | 19.4% | 7.4% | ||
| Q3 25 | 13.2% | 20.5% | ||
| Q2 25 | 24.2% | 20.8% | ||
| Q1 25 | 21.9% | 19.5% | ||
| Q4 24 | 24.2% | 15.3% | ||
| Q3 24 | 29.8% | 22.6% | ||
| Q2 24 | 30.3% | 24.3% | ||
| Q1 24 | 27.9% | 21.0% |
净利率AMPHCSW
| Q4 25 | 13.3% | 4.4% | ||
| Q3 25 | 9.0% | 14.7% | ||
| Q2 25 | 17.8% | 15.5% | ||
| Q1 25 | 14.8% | 15.2% | ||
| Q4 24 | 20.4% | 13.9% | ||
| Q3 24 | 21.1% | 15.8% | ||
| Q2 24 | 20.8% | 17.1% | ||
| Q1 24 | 25.1% | 15.1% |
每股收益（稀释后）AMPHCSW
| Q4 25 | $0.51 | $0.62 | ||
| Q3 25 | $0.37 | $2.41 | ||
| Q2 25 | $0.64 | $2.43 | ||
| Q1 25 | $0.51 | $2.05 | ||
| Q4 24 | $0.74 | $1.60 | ||
| Q3 24 | $0.78 | $2.26 | ||
| Q2 24 | $0.73 | $2.47 | ||
| Q1 24 | $0.81 | $2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $40.2M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $1.1B |
| 总资产 | $1.6B | $2.3B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHCSW
| Q4 25 | $282.8M | $40.2M | ||
| Q3 25 | $276.2M | $31.5M | ||
| Q2 25 | $231.8M | $38.0M | ||
| Q1 25 | $236.9M | $225.8M | ||
| Q4 24 | $221.6M | $213.8M | ||
| Q3 24 | $250.5M | $273.2M | ||
| Q2 24 | $217.8M | $18.9M | ||
| Q1 24 | $289.6M | $22.2M |
总债务AMPHCSW
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $800.1M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $166.0M |
股东权益AMPHCSW
| Q4 25 | $788.8M | $1.1B | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.1B | ||
| Q1 25 | $751.3M | $1.1B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $1.0B | ||
| Q2 24 | $713.3M | $650.2M | ||
| Q1 24 | $672.4M | $615.7M |
总资产AMPHCSW
| Q4 25 | $1.6B | $2.3B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.0B |
负债/权益比AMPHCSW
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 0.75× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $22.7M |
| 自由现金流率自由现金流/营收 | 13.4% | 9.8% |
| 资本支出强度资本支出/营收 | 4.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.35× | 2.81× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $162.0M |
8季度趋势，按日历期对齐
经营现金流AMPHCSW
| Q4 25 | $32.9M | $28.9M | ||
| Q3 25 | $52.6M | $61.8M | ||
| Q2 25 | $35.6M | $60.6M | ||
| Q1 25 | $35.1M | $27.3M | ||
| Q4 24 | $29.0M | $11.6M | ||
| Q3 24 | $60.0M | $66.8M | ||
| Q2 24 | $69.1M | $62.7M | ||
| Q1 24 | $55.3M | $22.4M |
自由现金流AMPHCSW
| Q4 25 | $24.6M | $22.7M | ||
| Q3 25 | $47.2M | $58.7M | ||
| Q2 25 | $25.0M | $57.7M | ||
| Q1 25 | $24.4M | $22.8M | ||
| Q4 24 | $16.6M | $8.5M | ||
| Q3 24 | $46.2M | $61.3M | ||
| Q2 24 | $63.1M | $59.6M | ||
| Q1 24 | $46.5M | $17.5M |
自由现金流率AMPHCSW
| Q4 25 | 13.4% | 9.8% | ||
| Q3 25 | 24.6% | 21.2% | ||
| Q2 25 | 14.3% | 21.9% | ||
| Q1 25 | 14.3% | 9.9% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 26.9% | ||
| Q2 24 | 34.6% | 26.3% | ||
| Q1 24 | 27.1% | 8.3% |
资本支出强度AMPHCSW
| Q4 25 | 4.5% | 2.6% | ||
| Q3 25 | 2.8% | 1.1% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 2.0% | ||
| Q4 24 | 6.7% | 1.6% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 5.1% | 2.3% |
现金转化率AMPHCSW
| Q4 25 | 1.35× | 2.81× | ||
| Q3 25 | 3.03× | 1.52× | ||
| Q2 25 | 1.15× | 1.48× | ||
| Q1 25 | 1.39× | 0.78× | ||
| Q4 24 | 0.76× | 0.43× | ||
| Q3 24 | 1.48× | 1.85× | ||
| Q2 24 | 1.82× | 1.62× | ||
| Q1 24 | 1.28× | 0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
